Opera Trading Capital acquired a new stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) during the 3rd quarter, Holdings Channel reports. The institutional investor acquired 11,134 shares of the company’s stock, valued at approximately $574,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. BB Biotech AG increased its stake in Ionis Pharmaceuticals by 1.8% in the 2nd quarter. BB Biotech AG now owns 8,666,334 shares of the company’s stock valued at $361,126,000 after buying an additional 150,000 shares during the period. Canada Pension Plan Investment Board increased its stake in Ionis Pharmaceuticals by 19.5% in the 2nd quarter. Canada Pension Plan Investment Board now owns 321,700 shares of the company’s stock valued at $13,405,000 after buying an additional 52,400 shares during the period. BlackRock Inc. increased its stake in Ionis Pharmaceuticals by 1.8% in the 2nd quarter. BlackRock Inc. now owns 7,054,579 shares of the company’s stock valued at $293,965,000 after buying an additional 124,233 shares during the period. Bellevue Group AG boosted its position in shares of Ionis Pharmaceuticals by 3.3% during the 2nd quarter. Bellevue Group AG now owns 322,586 shares of the company’s stock worth $13,442,000 after purchasing an additional 10,400 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Ionis Pharmaceuticals by 6.3% during the 2nd quarter. Bank of America Corp DE now owns 896,746 shares of the company’s stock worth $37,367,000 after purchasing an additional 53,503 shares in the last quarter. 85.87% of the stock is currently owned by institutional investors.

In related news, COO Brett P. Monia sold 16,493 shares of the business’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $54.00, for a total value of $890,622.00. Following the sale, the chief operating officer now directly owns 24,834 shares in the company, valued at approximately $1,341,036. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP C Frank Bennett sold 12,500 shares of the business’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $49.54, for a total transaction of $619,250.00. Following the completion of the sale, the senior vice president now owns 31,896 shares in the company, valued at $1,580,127.84. The disclosure for this sale can be found here. 2.44% of the stock is owned by insiders.

Shares of Ionis Pharmaceuticals stock traded down $0.14 on Monday, hitting $53.61. The company’s stock had a trading volume of 66,845 shares, compared to its average volume of 1,177,192. Ionis Pharmaceuticals Inc has a 52-week low of $39.07 and a 52-week high of $57.92. The company has a quick ratio of 7.96, a current ratio of 7.99 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $7.39 billion, a PE ratio of 670.06 and a beta of 2.39.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.10. Ionis Pharmaceuticals had a negative net margin of 7.52% and a negative return on equity of 1.58%. The business had revenue of $145.40 million for the quarter, compared to analyst estimates of $146.77 million. During the same period in the previous year, the firm earned ($0.02) EPS. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. On average, research analysts expect that Ionis Pharmaceuticals Inc will post -0.19 EPS for the current fiscal year.

Several equities research analysts have commented on IONS shares. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Piper Jaffray Companies set a $50.00 target price on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, November 6th. Morgan Stanley set a $46.00 target price on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 7th. Stifel Nicolaus boosted their target price on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a “hold” rating in a research report on Tuesday, September 25th. Finally, Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. Ionis Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $54.00.

TRADEMARK VIOLATION WARNING: “11,134 Shares in Ionis Pharmaceuticals Inc (IONS) Acquired by Opera Trading Capital” was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/11/19/11134-shares-in-ionis-pharmaceuticals-inc-ions-acquired-by-opera-trading-capital.html.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Featured Article: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.